Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France
Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Pacific Ridge Signs Exploration Agreements with Takla Nation for Kliyul and RDP
Making Strides: The Push to Democratize Private Equity
Where Does The IPO Market Go In 2025?
Japan In The Spotlight; Blockchain In AI's Shadow
Spectra7 and I-PEX to Demonstrate 800G Active Copper Internal Cables for Next Generation 25.6T Data Center Switches at OCP
Can ETFs Capture Private Equity Markets?
3 ETFs to Avoid as the S&P 500 Hit an All-Time Highs
PEX: Private Equity ETF, Small And Illiquid
This Week in ETFs: Private Equity Fund Debuts
Private Equity Valuations Withstand The Volatility Of 2022
Private Lenders Spy Opportunity
Should You Buy Private Equity ETFs Following Cathie Wood?
VPC: Private Credit ETF, Strong 6.6% Dividend Yield, But Better Choices Out There
PEX: Private Equity/BDC Index ETF, Fully-Covered 9.8% Dividend Yield, Asset Class Diversification
7 Index Funds to Buy For March